Cimetidine may improve survival in colorectal cancer
the ONA take:
According to new research published in the journal ecancermedicalscience, cimetidine, a histamine-2 receptor antagonist (H2RA), can improve survival in colorectal cancer.
Researchers from the Repurposing Drugs in Oncology (ReDO) project have found that cimetidine has positive effects in colorectal cancer, gastric cancer, melanoma, and renal cell carcincoma. Cimetidine would be an effective repurposed drug for cancer as it is very safe and has preclinical and clinical evidence of effectiveness for numerous types of cancer.
Furthermore, cimetidine is cheap and available over-the-counter. Cimetidine, like famotidine and ranitidine, works by inhibiting histamine receptors in the stomach, thereby decreasing the production of gastric acid.
The ReDO project has also found evidence of anti-cancer properties among clarithromycin, diclofenac, mebendazole, nitroglycerin, and itraconazole. Their findings suggest that these anti-cancer properties should be studied in clinical trials, but pharmaceutical companies lack the financial incentives to do so.
They note that repurposed drugs that are accessible, cheap, and have limited adverse effects are good alternatives to treat cancer in low- and middle-income countries and could reduce costs of treating cancer in developed countries.
Cimetidine, a histamine-2 receptor antagonist (H2RA), can improve survival in colorectal cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|